Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2022 - 01 - 04 save search
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
erbitux trial germany collaboration
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
PRQR | News | $2.0 -0.99% -1.0% 36K
|
Health Technology
|
| O: 0.37%
H: 6.04%
C: 3.45%
phase 2 phase 2/3 trial
Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201
Published: 2022-01-04 (Crawled : 22:00) - biospace.com/
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: 14.95%
H: 0.0%
C: 0.0%
cbp-201 phase 2 biopharma phase 2b trial conference
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
Published: 2022-01-04 (Crawled : 20:00) - biospace.com/
MNMD | $8.45 -4.74% -4.97% 830K
|
n/a
|
| O: -1.32%
H: 1.33%
C: -1.33%
trial phase 1 phase 2 phase 3
Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614
Published: 2022-01-04 (Crawled : 19:00) - biospace.com/
ENSC | $0.5583 1.58% 43K
|
Health Technology
|
| O: 4.43%
H: 4.23%
C: -8.93%
pf614 trial opioid bioscience
Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
Published: 2022-01-04 (Crawled : 19:00) - biospace.com/
SPRO | $1.41 -1.74% -1.77% 110K
|
Health Technology
|
| O: 3.96%
H: 0.0%
C: -5.33%
spr720 fda trial therapeutics
Global Industrial Gas Market for Flat Panel Display Market Report 2021-2026 Featuring Major Players - Linde Group, Air Liquide S.A., and Air Products and Chemicals
Published: 2022-01-04 (Crawled : 17:00) - prnewswire.com
APD | $234.68 0.42% -0.55% 1.3M
|
Process Industries
|
| O: 1.42%
H: 0.24%
C: -0.19%
als air trial group
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
RLAY | $6.34 7.46% 6.94% 1.7M
|
Health Technology
|
| O: 4.88%
H: 3.19%
C: -1.5%
rly-2608 expansion trial therapeutics
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
ALDX | $3.93 0.51% 0.51% 570K
|
Health Technology
|
| O: 0.7%
H: 2.33%
C: -1.4%
adx-2191 trial therapeutics phase 3 enroll
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 2.45%
H: 4.47%
C: 0.3%
ctp-543 als trial phase 3 enroll
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking CessationTopline ORCA-2 Results Expected in Q2 2022
Published: 2022-01-04 (Crawled : 15:00) - biospace.com/
ACHV | $4.53 0.67% 0.66% 32K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
trial results topline life science phase 3
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
Published: 2022-01-04 (Crawled : 14:00) - achievelifesciences.com
ACHV | $4.53 0.67% 0.66% 32K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
trial life science phase 3
Ethiopia Diesel Genset (Generator) Market Report 2021: Focus on Residential, Commercial, Industrial, Transportation & Public Infrastructure
Published: 2022-01-04 (Crawled : 12:30) - prnewswire.com
CMI | $292.34 -0.12% 0.0% 740K
|
Producer Manufacturing
|
| O: 0.58%
H: 0.0%
C: 0.0%
trial commercialization
Essentium Outlines How Industrial-Scale 3D Printing Unlocks New Value for Consumer Electronics Manufacturers at CES 2022
Published: 2022-01-04 (Crawled : 12:30) - prnewswire.com
ACAH | $10.45 0.0% 14K
|
|
| O: 0.0%
H: 0.46%
C: 0.46%
electronics trial
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
Published: 2022-01-04 (Crawled : 12:30) - globenewswire.com
AMYT | News | $14.7 0.0% 2.4M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
mycapssa trial diabetes positive results positive results phase 3 lancet
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.